How chronic inflammation tips the balance of immune cells to promote liver cancer

November 8, 2017
How chronic inflammation tips the balance of immune cells to promote liver cancer
Cytotoxic T cell (left) engaging a cancer cell (round cell, center). Credit: NIH

Chronic inflammation is known to drive many cancers, especially liver cancer. Researchers have long thought that's because inflammation directly affects cancer cells, stimulating their division and protecting them from cell death. But University of California San Diego School of Medicine researchers have now found that chronic liver inflammation also promotes cancer by suppressing immunosurveillance—a natural defense mechanism in which it's thought the immune system suppresses cancer development.

The study is published November 8 in Nature.

"Recent successes in immunotherapy—in the form of immune checkpoint inhibitors and adoptive T cell transfer—demonstrate how activated immune can eradicate tumors, but until now we didn't fully appreciate immunosurveillance or the role of adaptive immunity in tumor formation," said senior author Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology at UC San Diego School of Medicine. "This study provides one of the strongest and most direct demonstrations that adaptive immunity actively prevents ." Karin led the study with first author Shabnam Shalapour, PhD, an assistant professor in his group.

The team used a new mouse model of cancer in this study. Rather than artificially triggering cancer by engineering genetic mutations, this model more closely mimics human liver cancer in that tumors develop as a natural consequence of non-alcoholic steatohepatitis (NASH), a chronic metabolic disorder that causes , fibrosis and numerous cell mutations. NASH is associated with obesity and is expected to soon become the leading cause of liver cancer in the U.S. and other Western countries, Karin said.

The researchers found that NASH-associated mutations provoke the immune system, including cytotoxic T cells, to recognize and attack the newly emerging . However, chronic liver inflammation in both mice and humans also led to the accumulation of immunosuppressive lymphocytes, a type of immune cell Karin and Shalapour first described two years ago.

In the battle between these two types of , immunosuppressive lymphocytes win—they use a molecule known as PD-L1 to interfere with cytotoxic T cells. With the brake on T cells, liver tumors formed and grew in the chronically inflamed mice.

In mice that lacked tumor-fighting cytotoxic T cells, 27 percent of 15 mice had large liver tumors at six months. At that same point, mice retaining cytotoxic T cells had no tumors. Similarly, mice without immunosuppressive lymphocytes hardly had any tumors, even at 11 months, presumably since their absence left the cytotoxic T cells alone to do their -fighting job.

"PD-L1 allows immunosuppressive lymphocytes to suppress cytotoxic T cells, but it's also their 'Achilles heel,'" said Karin, who is also the Ben and Wanda Hildyard Chair for Mitochondrial and Metabolic Diseases.

When the researchers inhibited PD-L1 with a drug or by genetic engineering, immunosuppressive plasmocytes were eliminated from the liver, cytotoxic T cells were re-invigorated and they cleared the tumors.

"These findings provide an explanation for the remarkable ability of so-called anti-PD-1 drugs, which block the receptor for PD-L1, to induce liver cancer regression," Karin said. "The first member of this class of drugs was recently approved for the treatment of advanced liver cancer."

Karin, Shalapour and team are now working out how immunosuppressive lymphocyte are recruited to the liver. That information may reveal a way to interfere with the recruitment or generation of these cells, which could provide new means for liver cancer prevention or early treatment.

Liver cancer is the second leading cause of cancer deaths worldwide. Liver cancer is caused by chronic liver inflammation driven by hepatitis B or C, alcohol consumption, non-alcoholic fatty liver disease (NAFLD), or NASH. Currently, the only available treatment is surgical removal or ablation of tumors.

Explore further: Fat hormone linked to progression of fatty liver disease may hold key to new treatments

More information: Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity, Nature (2017). nature.com/articles/doi:10.1038/nature24302

Related Stories

Fat hormone linked to progression of fatty liver disease may hold key to new treatments

November 6, 2017
The rising obesity epidemic has brought with it an army of maladies. One, in particular, is threatening to outpace many of the disorders that accompany obesity, in terms of occurrence and severity: nonalcoholic fatty liver ...

Team finds a potentially better way to treat liver cancer

October 12, 2017
A Keck School of Medicine of USC research team has identified how cancer stem cells survive. This finding may one day lead to new therapies for liver cancer, one of the few cancers in the United States with an incidence rate ...

Fatty liver: Turning off TAZ reverses disease

October 27, 2016
Scientists at Columbia University Medical Center (CUMC) have identified a factor in liver cells that is responsible for turning a relatively benign liver condition, present in 30 percent of U.S. adults, into a serious disease ...

Of mice and cheeseburgers: Experimental drug reverses obesity-related liver disease

August 3, 2017
A drug developed at the University of Rochester Medical Center protected mice from one of the many ills of our cheeseburger and milkshake-laden Western diet—non-alcoholic fatty liver disease.

High levels of protein p62 predict liver cancer recurrence

May 19, 2016
Researchers at University of California San Diego School of Medicine and Sanford Burnham Prebys Medical Discovery Institute have discovered that high levels of the protein p62 in human liver samples are strongly associated ...

Research uncovers defender against cancer-promoting liver damage

October 10, 2016
Most cases of liver cancer develop after long-term viral infection, chronic exposure to alcohol, or excessive accumulation of fat in the liver due to obesity. The liver reacts to those insults by trying to wall it off with ...

Recommended for you

Researchers discover specific tumor environment that triggers cells to metastasize

November 21, 2017
A team of bioengineers and bioinformaticians at the University of California San Diego have discovered how the environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells ...

New study points the way to therapy for rare cancer that targets the young

November 21, 2017
After years of rigorous research, a team of scientists has identified the genetic engine that drives a rare form of liver cancer. The findings offer prime targets for drugs to treat the usually lethal disease, fibrolamellar ...

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.